InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
InMed Announces Results of 2024 Annual General Meeting
InMed Enters Into Standby Equity Purchase Agreement
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.